Rapport Therapeutics Files for IPO

TL;DR

Rapport Therapeutics is filing for an IPO to fund its CNS drug development.

AI Summary

Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, filed an S-1 registration statement on May 17, 2024, to register its securities for public offering. The company is focused on developing novel medicines for patients suffering from central nervous system disorders. Its principal executive offices are located at 1325 Boylston Street, Suite 401, Boston, MA 02215.

Why It Matters

This S-1 filing indicates Rapport Therapeutics is preparing to go public, which could provide significant capital for its drug development pipeline and potentially impact the availability of new treatments for CNS disorders.

Risk Assessment

Risk Level: medium — As a clinical-stage biopharmaceutical company, Rapport Therapeutics faces inherent risks associated with drug development, regulatory approvals, and market acceptance.

Key Numbers

• 333-279486 — SEC File Number (Identifies the specific registration statement with the SEC.)
• 2834 — SIC Code (Indicates the company operates in the Pharmaceutical Preparations industry.)

Key Players & Entities

• Rapport Therapeutics, Inc. (company) — Registrant
• May 17, 2024 (date) — Filing Date
• 1325 Boylston Street, Suite 401, Boston, MA 02215 (address) — Principal Executive Offices
• Abraham N. Ceesay, M.B.A. (person) — Chief Executive Officer
• Goodwin Procter LLP (company) — Legal Counsel

FAQ

Key Financial Figures

• $2.8 b — d market for epilepsy was approximately $2.8 billion, and this is expected to grow to
• $3.6 billion — is is expected to grow to approximately $3.6 billion by 2028. There are an estimated 1.8 mil

Filing Documents

• d803738ds1.htm (S-1) — 2547KB
• d803738dex31.htm (EX-3.1) — 121KB
• d803738dex33.htm (EX-3.3) — 69KB
• d803738dex41.htm (EX-4.1) — 1KB
• d803738dex42.htm (EX-4.2) — 180KB
• d803738dex101.htm (EX-10.1) — 186KB
• d803738dex1010.htm (EX-10.10) — 329KB
• d803738dex1011.htm (EX-10.11) — 87KB
• d803738dex1012.htm (EX-10.12) — 33KB
• d803738dex1013.htm (EX-10.13) — 83KB
• d803738dex1014.htm (EX-10.14) — 109KB
• d803738dex1015.htm (EX-10.15) — 105KB
• d803738dex211.htm (EX-21.1) — 2KB
• d803738dex231.htm (EX-23.1) — 2KB
• d803738dexfilingfees.htm (EX-FILING FEES) — 15KB
• g803738g00m02.jpg (GRAPHIC) — 40KB
• g803738g00m26.jpg (GRAPHIC) — 128KB
• g803738g00m27.jpg (GRAPHIC) — 134KB
• g803738g00m29.jpg (GRAPHIC) — 94KB
• g803738g00m30.jpg (GRAPHIC) — 108KB
• g803738g00m31.jpg (GRAPHIC) — 105KB
• g803738g00m33.jpg (GRAPHIC) — 112KB
• g803738g01g01.jpg (GRAPHIC) — 408KB
• g803738g02g02.jpg (GRAPHIC) — 245KB
• g803738g25c41.jpg (GRAPHIC) — 196KB
• g803738g35h11.jpg (GRAPHIC) — 141KB
• g803738g41i38.jpg (GRAPHIC) — 78KB
• g803738g56a01.jpg (GRAPHIC) — 80KB
• g803738g76c15.jpg (GRAPHIC) — 79KB
• g803738g91o98.jpg (GRAPHIC) — 122KB
• 0001193125-24-141704.txt ( ) — 6683KB

RISK FACTORS

RISK FACTORS 15 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 81

USE OF PROCEEDS

USE OF PROCEEDS 83 DIVIDEND POLICY 85 CAPITALIZATION 86

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 91

BUSINESS

BUSINESS 117 MANAGEMENT 166

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 177 DIRECTOR COMPENSATION 188 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 190 PRINCIPAL STOCKHOLDERS 194

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 198 SHARES ELIGIBLE FOR FUTURE SALE 204 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS 206

UNDERWRITING

UNDERWRITING 211 LEGAL MATTERS 219 EXPERTS 219 WHERE YOU CAN FIND ADDITIONAL INFORMATION 219 INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS F-1 Through and including, 2024 (the 25 th day after the date of this prospectus), all dealers effecting transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealers obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. Neither we nor the underwriters have authorized anyone to provide you any information or make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: we have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. We own

View Full Filing

View this S-1 filing on SEC EDGAR